Jessica E. Bath

Jessica E. Bath

Auto-generated profile, based on publicly available information

Jessica E. Bath

Department of Neurological Surgery, University California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2026 in Nature Medicine
Verified
Journal Article
Open access
KLKenneth H. Louie
Kenneth H. Louie
JBJannine P. Balakid
Jannine P. Balakid
JBJessica E. Bath
Jessica E. Bath
SSSeongmi Song
Seongmi Song
HAHamid Fekri Azgomi
Hamid Fekri Azgomi
DWDoris D. Wang
Doris D. Wang
A randomized crossover study of five patients with Parkinson’s disease (PD) demonstrates that gait-synchronized adaptive deep brain stimulation is feasible and safe, and reduces falls compared with continuous stimulation. Gait dysfunction in PD is a major source of disability and is often insufficiently treated by continuous deep brain stimulation (cDBS). Although adaptive DBS (aDBS) has shown efficacy for other motor symptoms using β-based, state-driven neural signals, gait is a dynamic, cyclical behavior that may require temporally precise modulation. Here we evaluated a behavior-contingent aDBS approach that synchronizes stimulation to gait phase. We reported a single-center, blinded, randomized, crossover study evaluating the feasibility of identifying patient-specific biomarkers to drive aDBS. The primary outcome was feasibility of successful identification of gait-phase biomarkers to implement aDBS. Five participants with PD undergoing pallidal DBS and subdural electrode paddle implantation were enrolled. We successfully identified personalized gait-phase biomarkers from cortical or pallidal field potentials in all five patients and embedded them into a bidirectional neurostimulator. During acute in-clinic testing, aDBS improved step variability and step symmetry versus cDBS. Three participants subsequently completed a double-blinded, multi-day crossover phase. In this setting, aDBS maintained general motor symptom control, reduced falls and yielded patient-specific gait improvements. No adverse events occurred and aDBS was well tolerated. These findings establish the feasibility of biomarker-driven, movement-synchronized neuromodulation and support the development of a larger randomized trial to determine clinical efficacy. ClinicalTrial.gov registration: NCT04675398 .

14 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
JBJessica E. Bath
Jessica E. Bath
KLKenneth H. Louie
Kenneth H. Louie
HAHamid Fekri Azgomi
Hamid Fekri Azgomi
JBJannine P. Balakid
Jannine P. Balakid
KPKara N. Presbrey
Kara N. Presbrey
DWDoris D. Wang
Doris D. Wang
Gait initiation is a fundamental human task, requiring one or more anticipatory postural adjustments (APA) prior to stepping. Deviations in amplitude and timing of APAs exist in Parkinson’s disease (PD), causing dysfunctional postural control which increases the risk of falls. The motor cortex and basal ganglia have been implicated in the regulation of postural control, however, their dynamics during gait initiation, relationship to APA metrics, and response to pharmacotherapy such as levodopa are unknown. To address these questions, we streamed electrocorticography (ECoG) potentials from the premotor and primary motor cortices, as well as local field potentials (LFPs) from the globus pallidus in five people with PD exhibiting gait and balance dysfunction during a cued gait initiation task. Amplitude and timing of APA were evaluated with force plates and synchronized to the neural data. Subjects performed gait initiation trials under ON and LOW levodopa conditions to assess effects of medication on APA metrics and underlying neural dynamics. All subjects demonstrated pallidal and cortical oscillatory changes during different phases of gait initiation. Grouped analysis revealed that from quiet standing to the first foot step, pallidal beta power showed stepwise decrease and broadband gamma power increases, whereas cortical potentials showed low frequency (theta, alpha, beta) power decrease during gait initiation, regardless of medication state. The pallidum and motor cortices also became increasingly coherent during gait initiation compared to quiet standing prior to APA onset. Using linear mixed models, we found that while pallidal gamma powers are predictive of APA scaling, pallidal-cortical coherence (theta, alpha, beta) and premotor-M1 gamma coherence are predictive of APA timing. Our study is the first detailed characterization of basal-ganglia cortical circuit dynamics during human gait initiation. We identified significant pallidal motor cortical power and coherence changes that underlie the amplitude and timing of APA which appear to be independent of medication states of the study subjects. Our results provide evidence for a model where synchronized premotor and motor cortical activities transiently couple with the globus pallidus to regulate the timing of postural responses, and local pallidal activity regulate the amplitude of postural changes during gait initiation. It suggests that abnormal pallidal outflow and synchronization between the pallidum and motor cortices may be a pathophysiological mechanism underlying disordered postural response in Parkinson’s disease.